OptimizeRx Corporation (OPRX) Stock

OptimizeRx Corporation (OPRX) is a Technology stock trading at $7.71 (as of 2026-08-21), with a market capitalization of $144.68M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OptimizeRx Corporation provides digital health messaging and support services for life sciences organizations, healthcare providers, and patients. Its offerings include financial messaging, a virtual patient support center for accessing medication support items, brand awareness and therapeutic reminder messaging, and related brand support services involving eRx media strategy and implementation, along with cloud-based mobile messaging platforms for patient engagement and medication adherence.

Understand OptimizeRx Corporation: how it makes money

OptimizeRx provides digital health communications, including virtual patient support and brand awareness and therapeutic messaging, sold to life sciences organizations, healthcare providers, and pharmaceutical customers, and it monetizes these solutions through contracted enterprise arrangements and related contracted revenue streams.

The business appears to convert enterprise deal activity into ongoing performance, where retention (Net Revenue Retention Rate) and pipeline visibility (Rolling 18-Month Pipeline and deal counts) are key indicators of how contracted communications offerings translate into continuing revenue.

Business quality (Weak): Clear product scope and measurable enterprise engagement KPIs, but the latest-quarter revenue is shown as 0.0B and segment reporting is not cleanly reconcilable from the provided data.

Valuation: Trades at 14× trailing earnings · $0B market cap.

Bull case

Retention suggests customers are, on net, expanding: Net Revenue Retention Rate is 110 percent, which is consistent with renewals and/or upsells within existing customer relationships.
Pipeline and deal activity provide a forward-looking visibility signal: Rolling 18-Month Pipeline is 0.22 USD_B, with 63 enterprise deals in pipeline and 52 enterprise deals closed (counts provided).

Bear case

Low operating profitability in the latest period: Operating margin is 2.0 percent, meaning earnings power is limited even with a gross margin of 75.2 percent.
Scale and reporting clarity are constraints for interpretation: Latest-quarter revenue is shown as 0.0B, and the provided segment breakdown does not cleanly reconcile to that total.
Customer concentration by customer-type could impact outcomes: Several operating KPIs reference top pharmaceutical manufacturers and customers, so changes in that customer base or their campaign needs could affect results.

Valuation — source: SEC EDGAR (first-party)
Price	$7.71
Market Cap	$144.68M
EV / EBITDA	18.9
Price / Book	1.12
Price / Sales	1.49
FCF Yield	16.1%
DCF Value (model)	$4.02
DCF Upside vs Price	-47.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$109.43M
Net Margin	4.7%
Revenue Growth (YoY)	18.8%
EPS Growth (YoY)	-125.5%
FCF Growth (YoY)	290.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.29 (grey)
Piotroski F-Score	8/9 (strong)

Valuation vs Sector & Industry
Sector P/E (Technology)	33.9
Industry P/E (Business Services)	29.9

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($13.94M)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Business Services
CEO	Stephen L. Silvestro
Employees	128
Country	US
IPO Date	2007-11-28

Related Companies (Business model: IT Services / Consulting and Managed Services; 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.